Mawer Investment Management Ltd. Sells 522,870 Shares of Becton, Dickinson and Company $BDX

Mawer Investment Management Ltd. lessened its position in Becton, Dickinson and Company (NYSE:BDX) by 49.0% in the fourth quarter, HoldingsChannel.com reports. The fund owned 543,136 shares of the medical instruments supplier’s stock after selling 522,870 shares during the period. Mawer Investment Management Ltd.’s holdings in Becton, Dickinson and Company were worth $105,406,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently modified their holdings of the company. Imprint Wealth LLC bought a new position in shares of Becton, Dickinson and Company in the 3rd quarter valued at about $25,000. Steph & Co. grew its position in shares of Becton, Dickinson and Company by 95.6% in the 4th quarter. Steph & Co. now owns 133 shares of the medical instruments supplier’s stock valued at $26,000 after acquiring an additional 65 shares during the period. WPG Advisers LLC grew its position in shares of Becton, Dickinson and Company by 64.2% in the 4th quarter. WPG Advisers LLC now owns 156 shares of the medical instruments supplier’s stock valued at $30,000 after acquiring an additional 61 shares during the period. Accredited Wealth Management LLC boosted its stake in shares of Becton, Dickinson and Company by 77.8% during the 3rd quarter. Accredited Wealth Management LLC now owns 160 shares of the medical instruments supplier’s stock worth $30,000 after acquiring an additional 70 shares during the period. Finally, Kohmann Bosshard Financial Services LLC bought a new position in shares of Becton, Dickinson and Company during the 4th quarter worth approximately $32,000. Institutional investors own 86.97% of the company’s stock.

Wall Street Analysts Forecast Growth

BDX has been the subject of several research analyst reports. Wells Fargo & Company lifted their target price on Becton, Dickinson and Company from $157.00 to $161.00 and gave the stock an “equal weight” rating in a research note on Friday, May 8th. Royal Bank Of Canada set a $175.00 target price on Becton, Dickinson and Company in a research note on Tuesday, April 14th. Argus reduced their target price on Becton, Dickinson and Company from $230.00 to $180.00 and set a “buy” rating for the company in a research note on Monday, March 23rd. Evercore lifted their target price on Becton, Dickinson and Company from $180.00 to $190.00 in a research note on Thursday, May 7th. Finally, Jefferies Financial Group reduced their target price on Becton, Dickinson and Company from $220.00 to $190.00 and set a “buy” rating for the company in a research note on Tuesday, February 10th. Seven analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Becton, Dickinson and Company has a consensus rating of “Hold” and an average price target of $183.64.

Becton, Dickinson and Company Stock Performance

BDX opened at $145.35 on Tuesday. The business has a fifty day simple moving average of $151.40 and a 200 day simple moving average of $176.68. The company has a market capitalization of $40.05 billion, a PE ratio of 36.80, a price-to-earnings-growth ratio of 10.42 and a beta of 0.22. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.94 and a quick ratio of 0.55. Becton, Dickinson and Company has a 1 year low of $127.59 and a 1 year high of $187.35.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share for the quarter, beating analysts’ consensus estimates of $2.77 by $0.13. The firm had revenue of $4.71 billion during the quarter, compared to the consensus estimate of $4.67 billion. Becton, Dickinson and Company had a return on equity of 15.37% and a net margin of 5.33%.The company’s revenue was up 5.2% compared to the same quarter last year. During the same period in the prior year, the company posted $3.35 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. Research analysts expect that Becton, Dickinson and Company will post 12.61 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 30th. Stockholders of record on Tuesday, June 9th will be given a dividend of $1.05 per share. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.9%. The ex-dividend date is Tuesday, June 9th. Becton, Dickinson and Company’s dividend payout ratio is presently 106.33%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.